Pretreatment with alanyl-glutamine suppresses T-helper-cell-associated cytokine expression and reduces inflammatory responses in mice with acute DSS-induced colitis

Journal of Nutritional Biochemistry

Volumn 23, Issue 9, 2012, Pages 1092-1099

  Chu, Chia Chou ^a   Hou, Yu Chen ^a   Pai, Man Hui ^a   Chao, Chen Jui ^a   Yeh, Sung Ling ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

DSS colitis; Glutamine; Haptoglobin; Immunoglobin G; T helper cells

Indexed keywords

ALANYLGLUTAMINE; AMINO ACID; CHEMOKINE; CYTOKINE; DEXTRAN SULFATE; GAMMA INTERFERON; HAPTOGLOBIN; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; INTERLEUKIN 4; MYELOPEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; COLITIS; COLON; CONTROLLED STUDY; ENTERITIS; ENZYME ACTIVITY; HELPER CELL; INFLAMMATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TH1 CELL; TH17 CELL; TH2 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS; COLITIS, ULCERATIVE; COLON; CYTOKINES; DEXTRAN SULFATE; DIPEPTIDES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HAPTOGLOBINS; INFLAMMATORY BOWEL DISEASES; INJECTIONS, INTRAPERITONEAL; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; PEROXIDASE; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, HELPER-INDUCER;

MUS;

EID: 84865091158     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.06.002     Document Type: Article

References (33)

1. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu Rev Immunol 2010, 28:573-621.
2. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002, 20:495-549.
3. Caprioli F., Pallone F., Monteleone G. Th17 immune response in IBD: a new pathogenic mechanism. J Crohns Colitis 2008, 2:291-295.
4. Abraham C., Cho J.H. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu Rev Med 2009, 60:97-110.
5. Wilmore D.W., Shabert J.K. Role of glutamine in immunologic responses. Nutrition 1998, 14:618-626.
6. Souba W.W. Glutamine: a key substrate for the splanchnic bed. Annu Rev Nutr 1991, 11:285-308.
7. Parry-Billings M., Evans J., Calder P.C., Newsholme E.A. Does glutamine contribute to immunosuppression after major burns?. Lancet 1990, 336:523-525.
8. Wilmore D.W. The effect of glutamine supplementation in patients following elective surgery and accidental injury. J Nutr 2001, 131:2543S-2599S. [discussion 2550S-1S].
9. Wischmeyer P.E., Kahana M., Wolfson R., Ren H., Musch M.M., Chang E.B. Glutamine reduces cytokine release, organ damage, and mortality in a rat model of endotoxemia. Shock 2001, 16:398-402.
10. Yeh C.L., Hsu C.S., Yeh S.L., Chen W.J. Dietary glutamine supplementation modulates Th1/Th2 cytokine and interleukin-6 expressions in septic mice. Cytokine 2005, 31:329-334.
11. Vicario M., Amat C., Rivero M., Moreto M., Pelegri C. Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis. J Nutr 2007, 137:1931-1937.
12. Alex P., Zachos N.C., Nguyen T., Gonzales L., Chen T.E., Conklin L.S., et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis 2009, 15:341-352.
13. Melgar S., Karlsson A., Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2005, 288:G1328-G1338.
14. Mok E., Constantin B., Favreau F., Neveux N., Magaud C., Delwail A., et al. l-Glutamine administration reduces oxidized glutathione and MAP kinase signaling in dystrophic muscle of mdx mice. Pediatr Res 2008, 63:268-273.
15. Suzuki K., Ota H., Sasagawa S., Sakatani T., Fujikura T. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem 1983, 132:345-352.
16. Iba Y., Sugimoto Y., Kamei C., Masukawa T. Possible role of mucosal mast cells in the recovery process of colitis induced by dextran sulfate sodium in rats. Int Immunopharmacol 2003, 3:485-491.
17. Kitajima S., Takuma S., Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim 1999, 48:137-143.
18. Dieleman L.A., Ridwan B.U., Tennyson G.S., Beagley K.W., Bucy R.P., Elson C.O. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994, 107:1643-1652.
19. Shintani N., Nakajima T., Okamoto T., Kondo T., Nakamura N., Mayumi T. Involvement of CD4+ T cells in the development of dextran sulfate sodium-induced experimental colitis and suppressive effect of IgG on their action. Gen Pharmacol 1998, 31:477-481.
20. Fuss I.J., Neurath M., Boirivant M., Klein J.S., de la Motte C., Strong S.A., et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996, 157:1261-1270.
21. Costa V.S., Mattana T.C., da Silva M.E. Unregulated IL-23/IL-17 immune response in autoimmune diseases. Diabetes Res Clin Pract 2010, 88:222-226.
22. Korn T., Oukka M., Kuchroo V., Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007, 19:362-371.
23. Colonna M. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 2009, 31:15-23.
24. Sonnenberg G.F., Nair M.G., Kirn T.J., Zaph C., Fouser L.A., Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010, 207:1293-1305.
25. Dieleman L.A., Palmen M.J., Akol H., Bloemena E., Peña A.S., Meuwissen S.G., et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998, 114:385-391.
26. Choudari C.P., O'Mahony S., Brydon G., Mwantembe O., Ferguson A. Gut lavage fluid protein concentrations: objective measures of disease activity in inflammatory bowel disease. Gastroenterology 1993, 104:1064-1071.
27. Macpherson A., Khoo U.Y., Forgacs I., Philpott-Howard J., Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996, 38:365-375.
28. Klebanoff S.J. Myeloperoxidase: friend and foe. J Leukoc Biol 2005, 77:598-625.
29. Sangfelt P., Carlson M., Thorn M., Loof L., Raab Y. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Am J Gastroenterol 2001, 96:1085-1090.
30. Sukhotnik I., Agam M., Shamir R., Shehadeh N., Lurie M., Coran A.G., et al. Oral glutamine prevents gut mucosal injury and improves mucosal recovery following lipopolysaccharide endotoxemia in a rat. J Surg Res 2007, 143:379-384.
31. Welbourne T.C. Ammonia production and glutamine incorporation into glutathione in the functioning rat kidney. Can J Biochem 1979, 57:233-237.
32. Yu J.C., Jiang Z.M., Li D.M., Yang N.F., M-X B. Alanyl-glutamine preserves hepatic glutathione stores after 5-FU treatment. Clin Nutr 1996, 15:261-265.
33. Babu R., Eaton S., Drake D.P., Spitz L., Pierro A. Glutamine and glutathione counteract the inhibitory effects of mediators of sepsis in neonatal hepatocytes. J Pediatr Surg 2001, 36:282-286.